InvestorsHub Logo

Lemmiwinks

05/21/20 5:30 PM

#275252 RE: Optionsrbest4u #275246

Like the study but a more powerful one IMO would be a retrospective one of patients that had been on V for a year versus patients not on V. See if there is a decrease in cardiac events, pulmonary embolism, stroke and ARDS type lung issues in patients with covid that had the benefit of the remodeling and anti inflammatory effects of V on the endothelium etc for at least a year.
Lem-

Dancing in the dark

05/21/20 8:19 PM

#275309 RE: Optionsrbest4u #275246

"Obviously assuming the trial indicates efficacy or trend towards efficacy (it is only a 2 week course after all) and so justifies a more thorough, longer course of treatment. "

P.s. let us ask NIH to fund a longer Vascepa covid-19 trial just like hydrochloroquie and azithromycin.